Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Novartis   20 days ago
ads
Read Full Story
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease  NovartisNovartis scores double phase 3 win in Sjögren's syndrome, succeeding where rivals failed  Fierce BiotechNovartis’s...